'Intriguing' data On GSK's ICOS Agonist For Head And Neck Cancer

While much of the focus at the European Society for Medical Oncology congress was on its PARP inhibitor Zejula, GlaxoSmithKline PLC also used the Barcelona meeting to tout promising early data on its investigational inducible T-cell co-stimulatory (ICOS) agonist for head and neck cancer.

The UK drugs major unveiled data showing that GSK3359609, an ICOS agonist designed to selectively enhance T cell function, demonstrated promising anti-tumor activity in combination with Merck & Co....